MG
IBRX icon

Michael Gelband’s ImmunityBio IBRX Stock Holding History

Michael Gelband’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Buy
193,340
+109,031
+129% +$825K 0.01% 886
2026
Q1 		$647K Sell
84,309
-283,572
-77% -$1.94M 0.01% 1120
2025
Q4 		$728K Buy
367,881
+205,498
+127% +$466K 0.01% 1090
2025
Q3 		$399K Buy
+162,383
New +$418K ﹤0.01% 1237
2024
Q4 		– Sell
-135,029
Closed -$502K – 1748
2024
Q3 		$502K Buy
+135,029
New +$625K ﹤0.01% 1183
2024
Q1 		– Sell
-23,558
Closed -$118K – 1695
2023
Q4 		$118K Buy
+23,558
New +$73.9K ﹤0.01% 1341
2023
Q2 		– Sell
-10,262
Closed -$19K – 2030
2023
Q1 		$19K Buy
+10,262
New +$31.9K ﹤0.01% 1691
2021
Q2 		– Sell
-35,312
Closed -$838K – 2556
2021
Q1 		$838K Buy
+35,312
New +$915K 0.01% 1019
2020
Q4 		– Sell
-11,892
Closed -$82K – 2137
2020
Q3 		$82K Sell
11,892
-85,579
-88% -$853K ﹤0.01% 1612
2020
Q2 		$1.2M Buy
97,471
+15,850
+19% +$89.5K 0.03% 652
2020
Q1 		$235K Sell
81,621
-10,532
-11% -$52.7K 0.01% 722
2019
Q4 		$349K Buy
+92,153
New +$157K 0.01% 1058

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Michael Gelband's IBRX Position: Q2 2026 in Review

Michael Gelband increased its ImmunityBio (IBRX) stake by 129% in Q2 2026, buying an estimated $825K and bringing the position to 193,340 shares worth $1.69M. The position accounts for 0.01% of the portfolio, ranked #886.

Michael Gelband first reported a position in IBRX in Q4 2019 and has held it in 12 quarters since. 402 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Michael Gelband held 193,340 shares of ImmunityBio worth $1.69M as of Q2 2026.
  • Michael Gelband bought 109,031 ImmunityBio shares in Q2 2026, an estimated $825K.
  • ImmunityBio made up 0.01% of Michael Gelband's portfolio in Q2 2026, its #886 holding.
  • Michael Gelband first reported a position in ImmunityBio in Q4 2019 and has held it in 12 quarters since.
  • 402 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.